PureTech Health PLC (LSE:PRTC) has spent 2026 rebuilding itself as a leaner holding company. In five months it has floated one founded entity on Nasdaq, spun its lead drug programme into a separately funded company, walked away from its own Nasdaq listing and installed a new chief executive to run what remains.
The question for London investors is whether the market has caught up. At 31 March 2026 PureTech held $248.1m of parent-level cash, and its stake in newly listed Seaport Therapeutics was worth roughly $300m at that company's IPO price. Against that sits a Market Capitalisation of about £295m on Hargreaves Lansdown's data page. Whether that gap is an opportunity or a fair discount for clinical risk is the debate this article examines.
Celea spin-out: $180m raised, Phase 3 under way and a lean parent left behind
The most consequential development came on 2 July 2026, when PureTech transferred its deupirfenidone (LYT-100) programme for idiopathic pulmonary fibrosis (IPF) into a new company, Celea Therapeutics, alongside a $180m Series Seed financing. External investors led by RA Capital Management and Leaps by Bayer, joined by a large US healthcare fund and a sovereign Wealth fund, put in $150m; PureTech added $30m. The first $75m closed on 29 June 2026 at $1.93 per share, valuing Celea at $302.5m post-money.
PureTech retains a 35.4% fully diluted stake plus 40 million junior Preferred Shares carrying a $1.93 Liquidation preference. It also keeps tiered royalties of 1% to 3% of net sales, up to $190m in milestones (including $15m on first US commercial sale and $100m if annual sales reach $3bn) and 20% of any sublicence income, and has earmarked $70m of existing cash for future Celea rounds.
The logic is cost. Deupirfenidone accounted for roughly 70% of PureTech's external Research and Development spend, and those costs now sit outside the group. Chief executive Robert Lyne called the financing "a transformative milestone for both PureTech and Celea" that "enables PureTech's transition to a lean operating model while maintaining meaningful ownership in Celea and significant long-term economic upside."
Celea moved quickly. On 13 July 2026 it dosed the first patient in SURPASS-IPF, a roughly 1,100-patient Phase 3 trial across more than 30 countries comparing deupirfenidone head-to-head against pirfenidone over 52 weeks, with change in forced vital capacity as the primary endpoint. Topline data are expected in the second half of 2029. On 25 August 2026 PureTech confirmed two Celea presentations at the European Respiratory Society congress in Barcelona from 5 to 9 September.
What PureTech actually is now
PureTech is a clinical-stage biotherapeutics company that creates and funds new medicines, then spins them into "founded entities" that raise third-party capital; those entities have secured more than $4bn of outside funding since 2018, according to the FY2025 results. Its best-known success is Karuna Therapeutics, maker of the schizophrenia drug Cobenfy, which Bristol Myers Squibb bought in March 2024. PureTech says it has realised about $1.1bn in cash from an initial $18.5m Investment and keeps a 2% Royalty on annual Cobenfy sales above $2bn.
The portfolio now has three main legs. Seaport Therapeutics, developing Glyph-platform neuropsychiatry drugs, priced an upsized Nasdaq IPO on 1 May 2026, selling 14.16 million shares at $18 for gross proceeds of $254.9m; PureTech held 16,685,013 shares at closing and is entitled to 3% to 5% royalties on Glyph product sales. Celea is the second. The third is wholly owned Gallop Oncology, whose LYT-200 antibody reported positive Phase 1 topline data in blood cancers on 22 April 2026, with an external financing targeted for the first quarter of 2027. Legacy holdings in Vedanta, Entrega and Sonde Health are described as non-material.
PureTech has no product Revenue of its own; income comes from royalties, milestones, disposals and Equity stakes, so the Balance Sheet and pipeline matter more than the profit and loss account.
FY2025 results: cash falls to $277m, runway to end-2028
Final results for the year to 31 December 2025, published on 29 April 2026, showed PureTech-level cash, cash equivalents and short-term investments of $277.1m, down from $366.8m a year earlier. By 31 March 2026 the figure was $248.1m. Management guided to an operational runway "at least through the end of 2028", including expected participation in founded-entity fundraisings, and said the Celea deal would leave "a lower and more predictable cost base".
Third-party data from Hargreaves Lansdown put FY2025 revenue at $4.66m and the net loss at $109.7m, with loss per share widening to $0.46 from $0.18 in FY2024; those figures could not be checked against the full RNS tables and should be read as indicative. There is no dividend, although around $150m has been returned to shareholders to date. There are 261.42 million shares in issue.
Alongside the results PureTech announced the voluntary delisting of its American Depositary Shares from Nasdaq, with a last trading day of 20 May 2026 and a Form 15F filing to end SEC reporting; Lyne framed the move as "streamlining overhead, preserving capital" and concentrating on London, where most trading already took place.
What could move the shares next
The nearest fixed point is the 2026 half-year report; last year's arrived on 28 August, so an update on cash burn under the new model should be imminent. Seaport's share price now provides a daily mark for PureTech's largest listed asset, and Seaport's Phase 2b BUOY-1 readout is guided for the first half of 2027. Gallop's planned financing in early 2027 would repeat the Celea template. Cobenfy's sales trajectory determines when the 2% royalty above $2bn starts to pay. Longer term, SURPASS-IPF topline data in the second half of 2029 is the binary event for Celea and for PureTech's stake, royalties and $190m milestone ladder.
Risks investors should watch
Clinical risk dominates. Deupirfenidone must beat an approved drug head-to-head, a higher bar than placebo. Cash is finite: parent cash fell almost $90m during 2025, and the $70m reserved for Celea plus Gallop funding could absorb more. Value is concentrated in three assets, and the Seaport stake is exposed to Nasdaq biotech sentiment and lock-up dynamics. Ending SEC reporting may thin the US investor base. Royalty and milestone income depends on partners' commercial execution, and FX matters for sterling holders of a dollar balance sheet.
Outlook
PureTech has converted a costly single-asset bet into a portfolio of externally funded stakes and a smaller cost base, and management has told the market where the runway ends. What it has not yet done is show the lower Burn Rate in reported numbers. The half-year figures, the Seaport share price and Gallop's financing are the near-term tests; SURPASS-IPF in 2029 is the long-term one. Investors weighing the headline question should track how cash and stakes evolve against Market Value rather than assume either side of the ledger is fixed.






Please wait processing your request...